BeiGene Stock Meets 80-Plus RS Rating Benchmark

Blockhead

01-16

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene (ONC) stock just hit that mark, with a jump from 69 to 84 Wednesday.

↑ X NOW PLAYING This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts

IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.

History reveals that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Is BeiGene Stock A Buy?

BeiGene stock reclaimed its 50-day moving average on Tuesday and is working on a consolidation with a 248.16 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.

The oncology biotech company showed 0% EPS growth last quarter. Sales rose 28%.

BeiGene stock earns the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."

YOU MAY ALSO LIKE:

Learn How To Time The Market With IBD's ETF Market Strategy

Find Today's Best Growth Stocks To Watch With IBD 50

Find The Best Long-Term Investments With IBD Long-Term Leaders

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2503067205"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503067205\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503067205?lang=zh_CN&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2017/05/IRU4-150x150.jpg","is_english":true,"pubTime":"2025-01-16 04:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503067205","market":"us","top_or_hot":-1,"title":"BeiGene Stock Meets 80-Plus RS Rating Benchmark","media":"Blockhead","content":"<html><body><div>\n<p>One important metric to look for in a stock is an 80 or higher Relative Strength Rating. <b>BeiGene</b> (ONC) stock just hit that mark, with a jump from 69 to 84 Wednesday.</p>\n<span>\n<span>\n<span jw-video-key=\"P60da92U\" vid-authors=\"MEREDITH HEYMAN\" vid-cat=\"Industry Insights\" vid-date=\"01/02/2025\" vid-date-tmsp=\"1735802129\" vid-dom-id=\"9599934-678821f15d447\" vid-id=\"9599934\" vid-image=\"https://www.investors.com/wp-content/uploads/2024/12/P60da92U-640x360.jpg\" vid-name=\"This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/P60da92U.m3u8\" vid-width=\"50\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span>NOW PLAYING</span>\n<span>This Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts</span>\n</span>\n</span>\n</span>\n</span>\n<p>IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.</p>\n<p>History reveals that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.</p>\n<hr/>\n<p>Looking For The Best Stocks To Buy And Watch? Start Here</p>\n<hr/>\n<h2>Is BeiGene Stock A Buy?</h2>\n<p>BeiGene stock reclaimed its 50-day moving average on Tuesday and is working on a consolidation with a 248.16 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.</p>\n<div><div></div></div>\n<p>The oncology biotech company showed 0% EPS growth last quarter. Sales rose 28%.</p>\n<p>BeiGene stock earns the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. <b>Catalyst Pharmaceuticals</b> (CPRX), <b>Exelixis</b> (EXEL) and <b>Halozyme <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></b> (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"</p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p><span>Learn How To Time The Market With IBD's ETF Market Strategy</span></p>\n<p><span>Find Today's Best Growth Stocks To Watch With IBD 50</span></p>\n<p><span>Find The Best Long-Term Investments With IBD Long-Term Leaders</span></p>\n<p><span>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</span></p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BeiGene Stock Meets 80-Plus RS Rating Benchmark</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Stock Meets 80-Plus RS Rating Benchmark\n</h2>\n<h4 class=\"meta\">\n\n\n2025-01-16 04:44 GMT+8   <a href=\"https://www.investors.com/news/beigene-stock-meets-80-plus-rs-rating-benchmark/\"><strong>Blockhead</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene (ONC) stock just hit that mark, with a jump from 69 to 84 Wednesday.\n\n\n\n↑\nX\n\nNOW PLAYING\nThis Is How ...</p>\n<a href=\"https://www.investors.com/news/beigene-stock-meets-80-plus-rs-rating-benchmark/\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"https://www.investors.com/news/beigene-stock-meets-80-plus-rs-rating-benchmark/","article_id":"2503067205","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/05/IRU4-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503067205","pubTimestamp":1736973840,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"BeiGene ADR sees its Relative Strength Rating move into the 80-plus level.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州","RS":"Reliance Steel & Aluminum Co"},"translate_title":"百济神州股票达到80多RS评级基准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1,"RS":1},"content_text":"One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene (ONC) stock just hit that mark, with a jump from 69 to 84 Wednesday.\n\n\n\n↑\nX\n\nNOW PLAYING\nThis Is How 2025 Jobs Reports Will Impact The Fed And Rate Cuts\n\n\n\n\nIBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.\nHistory reveals that the market's biggest winners often have an RS Rating of at least 80 in the early stages of their moves.\n\nLooking For The Best Stocks To Buy And Watch? Start Here\n\nIs BeiGene Stock A Buy?\nBeiGene stock reclaimed its 50-day moving average on Tuesday and is working on a consolidation with a 248.16 entry. See if the biotech stock can clear the breakout price in volume at least 40% above average.\n\nThe oncology biotech company showed 0% EPS growth last quarter. Sales rose 28%.\nBeiGene stock earns the No. 111 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Halozyme Therapeutics (HALO) are among the top 5 highly rated stocks within the group. For more industry news, check out \"Biotech And Pharmaceutical Industry And Stock News.\"\nYOU MAY ALSO LIKE:\nLearn How To Time The Market With IBD's ETF Market Strategy\nFind Today's Best Growth Stocks To Watch With IBD 50\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}